## YieldMax MRNA Option Income Strategy ETF Schedule of Investments as of January 31, 2024 (Unaudited)

U.S. TREASURY OBLIGATIONS - 51.3%		Par		Value
United States Treasury Note/Bond, 0.75%, 11/15/2024 <sup>(a)</sup>		\$ 11,620,000	\$	11,253,221
TOTAL U.S. TREASURY OBLIGATIONS (Cost \$11,251,353)				11,253,221
OPTIONS PURCHASED - 5.7% <sup>(b)(c)</sup>	Notional Amount	Contracts		
Call Options - 5.7%				
Moderna, Inc., Expiration: 03/15/2024; Exercise Price: \$105.00 <sup>(d)(e)</sup>	21,877,325	2,165		1,244,875
TOTAL OPTIONS PURCHASED (Cost \$2,684,531)				1,244,875
SHORT-TERM INVESTMENTS - 46.4%		Shares		
Money Market Funds - 0.5%				
First American Government Obligations Fund - Class X, $5.25\%^{(f)}$		100,882	. <u> </u>	100,882
U.S. Treasury Bills - 45.9%		Par		
5.17%, 06/13/2024 <sup>(g)</sup>		10,260,000		10,068,438
TOTAL SHORT-TERM INVESTMENTS (Cost \$10,169,371)				10,169,320
TOTAL INVESTMENTS - 103.4% (Cost \$24,105,255)			\$	22,667,416
Liabilities in Excess of Other Assets - (3.4)%				(746,349)
TOTAL NET ASSETS - 100.0%			\$	21,921,067

Percentages are stated as a percent of net assets.

(a) This security was held in its entirety at the broker in connection with options as of January 31, 2024.

- (b) Exchange-traded.
- (c) 100 shares per contract.
- (d) Held in connection with written option contracts. See Schedule of Options Written for further information.
- (e) Non-income producing security.
- (f) The rate shown represents the 7-day effective yield as of January 31, 2024.
- (g) The rate shown is the effective yield.

## YieldMax MRNA Option Income Strategy ETF Schedule of Options Written as of January 31, 2024 (Unaudited)

OPTIONS WRITTEN - (9.4)% <sup>(a)(b)</sup>	Notional Amount	Contracts	Value
Call Options - (0.3)%			
Moderna, Inc.			
Expiration: 02/02/2024; Exercise Price: \$110.00	\$ (353,675)	(35)	\$ (280)
Expiration: 02/02/2024; Exercise Price: \$107.00	(20,210,000)	(2,000)	(44,000)
Expiration: 02/09/2024; Exercise Price: \$108.00	(1,313,650)	(130)	(13,000)
Total Call Options			 (57,280)
Put Options - (9.1)%			
Moderna, Inc., Expiration: 03/15/2024; Exercise Price: \$105.01 <sup>(c)</sup>	(21,877,325)	(2,165)	(2,003,443)
TOTAL OPTIONS WRITTEN (Premiums received \$1,962,452)			\$ (2,060,723)

Percentages are stated as a percent of net assets.

(a) Exchange-traded.

(b) 100 shares per contract.

(c) FLexible EXchange<sup>®</sup> Options

## Summary of Fair Value Exposure at January 31, 2024 (Unaudited)

The Fund utilizes various methods to measure the fair value of its investments on a recurring basis. U.S. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of inputs are:

• Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.

• Level 2 — Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment spreads, credit risk, yield curves, default rates and similar data.

• Level 3 — Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The following is a summary of the inputs used to value the Fund's investments as of January 31, 2024:

## YieldMax MRNA Option Income Strategy ETF

	Level 1	Level 2	Level 3	<u>Total</u>
Assets:				
U.S. Treasury Obligations	\$ -	\$ 11,253,221	\$ _	\$ 11,253,221
Options Purchased	1,244,875	_	-	1,244,875
Money Market Funds	100,882	_	_	100,882
U.S. Treasury Bills	-	10,068,438	-	10,068,438
Total Assets	\$ 1,345,757	\$ 21,321,659	\$ -	\$ 22,667,416
Liabilities:				
Options Written	(44,280)	(2,016,443)	-	(2,060,723)
Total Liabilities	\$ (44,280)	\$ (2,016,443)	\$ -	\$ (2,060,723)